Investor Presentation Full Year 2021

45 Investor presentation Full year 2021 Once-weekly insulin icodec represents a new treatment paradigm in the diabetes portfolio The phase 3 programme for insulin icodec was initiated in 2020 ONWARDS 1 970 people treatment naive, 78-week, vs. glargine U100 ONWARDS 2 ONWARDS 3 ONWARDS 4 520 people on basal, 26-week, vs. degludec 580 people treatment naive, 26-week, vs. degludec 580 people on both basal and bolus, 26-week, vs. glargine + aspart ONWARDS 5 1,100 people, insulin naïve using app-based dosing recommendations, 52-week ONWARDS 6 2020 Note: Trial conclusion indicated by last patient last visit (LPLV) 580 people, type 1 diabetes using bolus insulin, 52-week, vs. degludec 2021 2022 Novo NordiskⓇ

View entire presentation